Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.
We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to evaluate tumor response, adverse effects, and survival in men with castrate resistant prostate cancer who had exhausted all other potential approved therapies, evaluated the novel radioligand therapy with Lu-PSMA-617. Fifty therapies using Lu-PSMA-617 were performed in 28 consecutive men with mCRPC. Data were retrospectively analyzed [...]